Across the global life sciences industry, the early stages of clinical development are increasingly recognized as decisive inflection points that determine the long-term trajectory of therapeutic candidates. Organizations entering this first-in-human phase must navigate a complex landscape where safety, dose escalation, and biological response patterns are carefully measured. As...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek